{
    "clinical_study": {
        "@rank": "36909", 
        "arm_group": [
            {
                "arm_group_label": "Levosimendan", 
                "arm_group_type": "Experimental", 
                "description": "levosimendan 0.2 \u00b5g/kg/min for first hour, followed by 0.1 \u00b5g/kg/min for an additional 23 hours"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo 0.2 \u00b5g/kg/min for first hour, followed by 0.1 \u00b5g/kg/min for an additional 23 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate levosimendan compared with placebo in reducing the composite event rate\n      of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist\n      (IABP or LVAD) in subjects with reduced ejection fraction undergoing cardiac surgery on\n      cardiopulmonary bypass (CPB)."
        }, 
        "brief_title": "Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Bypass Grafting", 
            "Mitral Valve Surgery", 
            "Low Cardiac Output Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiac Output, Low", 
                "Ventricular Dysfunction, Left"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is being done to evaluate the efficacy of levosimendan compared with placebo in\n      reducing the co-primary endpoints of 30-day composite of all-cause death or use of\n      mechanical assist device (IABP or LVAD) or the composite event rate of all-cause death,\n      perioperative MI, need for dialysis, or use of mechanical assist (IABP or LVAD) in subjects\n      with reduced ejection fraction undergoing cardiac surgery on CPB."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented LVEF \u226425% measured by nuclear scan, echocardiogram (ECHO), or\n             ventriculogram, within 60 days before surgery.\n\n          -  Scheduled to undergo 1) CABG surgery with or without mitral valve replacement, or 2)\n             isolated mitral valve repair; all patients on CPB.\n\n          -  Signed (by the subjects or their legally acceptable representatives) informed consent\n             document indicating that they understand the purpose of and procedures required for\n             the study and are willing to participate in the study\n\n        Exclusion Criteria:\n\n          -  Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive\n             pericarditis, pericardial tamponade, or other conditions in which cardiac output is\n             dependent on venous return.\n\n          -  Pulmonary disease (severe chronic obstructive pulmonary disease [COPD], asthma, or\n             other condition) that, in the opinion of the investigator, represents an independent\n             clinical risk to the cardiac surgery and recovery of the patient.\n\n          -  Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours\n             before surgery.\n\n          -  Chronic dialysis at baseline or within 30 days of CABG/mitral valve surgery (either\n             hemodialysis, peritoneal dialysis, continuous venovenous hemodialysis).\n\n          -  Estimated glomerular filtration rate (eGFR) < 30 mL/kg/min or evidence of worsening\n             renal function before CABG/mitral valve surgery.\n\n          -  Weight \u2265 170 kg.\n\n          -  Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study\n             drug.\n\n          -  Heart rate \u2265 120 bpm, persistent for at least 10 minutes.\n\n          -  Hemoglobin < 80 g/L within 4 hours before baseline.\n\n          -  Serum potassium < 3.5 mmol/L at baseline.\n\n          -  A history of Torsades de Pointes.\n\n          -  Mechanical assist device (IABP, LVAD) in previous 30 days or pre-planned use of IABP\n             or LVAD during or following CABG/mitral valve surgery.\n\n          -  Patients with aortal femoral inclusive disease that would prohibit use of IABP.\n\n          -  Planned aortic valve repair or replacement.\n\n          -  Liver dysfunction Child Pugh Class B or C (see Attachment 3)\n\n          -  Patients having severely compromised immune function\n\n          -  Pregnant, suspected to be pregnant, or breast-feeding.\n\n          -  Received an experimental drug or used an experimental medical device in previous 30\n             days.\n\n          -  Known allergic reaction or sensitivity to Levosimendan or excipients.\n\n          -  Received commercial Levosimendan within 30 days before the planned start of study\n             drug.\n\n          -  Employees of the investigator or study center, with direct involvement in the\n             proposed study or other studies under the direction of that investigator or study\n             center, as well as family members of the employees or the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "760", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025621", 
            "org_study_id": "PYX-LVO-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levosimendan", 
                "intervention_name": "Levosimendan", 
                "intervention_type": "Drug", 
                "other_name": "Simdax"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simendan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "coronary artery bypass grafting", 
            "CABG", 
            "mitral valve", 
            "LCOS", 
            "low cardiac output syndrome", 
            "levosimendan"
        ], 
        "lastchanged_date": "December 30, 2013", 
        "location": {
            "contact": {
                "email": "raj.mehta@duke.edu", 
                "last_name": "Rajendra Mehta, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Raleigh", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass", 
        "other_outcome": [
            {
                "measure": "Occurrence of all-cause mortality from randomization through Day 90", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Postoperative incidence of atrial fibrillation", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }, 
            {
                "measure": "Rehospitalization for any cause through Day 30", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "overall_contact": {
            "email": "d.hay@oxybiomed.com", 
            "last_name": "Douglas Hay, PhD", 
            "phone": "919-855-2110"
        }, 
        "overall_official": [
            {
                "affiliation": "Duke Clinical Research Institute", 
                "last_name": "Rajendra Mehta, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Duke Clinical Research Institute", 
                "last_name": "John Alexander, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The all-cause death at 30 days or use of mechanical assist device (IABP, LVAD following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) through Day 5", 
                "measure": "Co-primary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Composite of all-cause death (at 30 days), or perioperative nonfatal MI (through Day 5) [CK-MB >10xULN or >100 ng/mL, CK-MB >5xULN or 50 ng/mL with new Q wave (>0.04 seconds wide in two contiguous leads) or new left bundle branch block)], or need for renal dialysis (through Day 30), or use of mechanical assist device (IABP or LVAD following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) (through Day 5)", 
                "measure": "Co-primary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Duration of intensive care unit/critical or coronary care unit (ICU/CCU) length of stay (LOS)", 
                "measure": "Duration of intensive care unit/critical or coronary care unit (ICU/CCU)", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for during the participant's hospital stay up to 30 days"
            }, 
            {
                "description": "Incidence of LCOS defined as cardiac index \u2264 2.0 L/min/m2 for  \u226530 minutes despite optimal fluid balance and maximal inotropic support (dobutamine, milrinone, epinephrine, norepinephrine), with the fluid balance and maximal inotropic dose at the investigator's discretion)", 
                "measure": "Incidence of LCOS defined as cardiac index \u2264 2.0 L/min/m2 for  \u226530 minutes despite optimal fluid balance and maximal inotropic support (dobutamine, milrinone, epinephrine, norepinephrine)", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "measure": "Postoperative use of secondary inotrope (dobutamine, milrinone, epinephrine, and norepinephrine) associated with index surgical procedure", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "source": "Oxygen Biotherapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxygen Biotherapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}